08:55 AM EDT, 09/11/2024 (MT Newswires) -- Actuate Therapeutics ( ACTU ) said Wednesday that the US Food and Drug Administration has granted orphan drug designation to elraglusib to treat soft tissue sarcoma.

The designation is intended to support companies developing medicines for rare disorders that affect fewer than 200,000 people in the US.

Shares of the biopharmaceutical company were up 2.4% in recent premarket activity.

Price: 8.40, Change: +0.20, Percent Change: +2.44